Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TLR4 | O00206 | 4/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15364870 | 1.00 | MCL1 (0.52) | MCL1KMT2AMAPK1CA1CA2 | |
| SCHEMBL63339 | 0.98 | MCL1 (0.53) | MCL1KMT2AMAPK1CA1CA2 | |
| SCHEMBL29010313 | 0.96 | MCL1 (0.52) | MCL1KMT2AMAPK1CA1CA2 | |
| SCHEMBL31387265 | 0.96 | MCL1 (0.52) | MCL1KMT2AMAPK1CA1CA2 | |
| SCHEMBL27710740 | 0.96 | MCL1 (0.52) | MCL1KMT2AMAPK1CA1CA2 | |
| SCHEMBL11114524 | 0.96 | MCL1 (0.52) | MCL1KMT2AMAPK1CA1CA2 | |
| SCHEMBL28643556 | 0.96 | MCL1 (0.52) | MCL1KMT2AMAPK1CA1CA2 | |
| SCHEMBL6914585 | 0.96 | MCL1 (0.52) | MCL1KMT2AMAPK1CA1CA2 | |
| Zinc Ion SCHEMBL31034477 | 0.96 | MCL1 (0.52) | MCL1KMT2AMAPK1CA1CA2 | |
| Hydrochloric Acid SCHEMBL11275817 | 0.94 | MCL1 (0.50) | MCL1KMT2AMAPK1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340644-B2 | Self-sensitive polymerizable liquid resin and use thereof | ETERNAL MATERIALS CO., LTD. (TW) | 2016-05-17 | — | — | US | claimed |
| EP-4632110-A1 | PROCESS FOR THE HALOGENATION OF ORGANIC COMPOUNDS | ESy-Labs-GmbH (DE) | 2025-10-15 | — | — | EP | disclosed |
| WO-2019025575-A1 | PROCESSES FOR PREPARING COMPLEXES COMPRISING RHODIUM(II) AND CARBOXYLATE LIGANDS | STOCKHOLM UNIVERSITY HOLDING AB (SE) | 2019-02-07 | — | — | WO | disclosed |
| WO-2017129991-A2 | PROCESSES FOR PREPARING STERICALLY CONGESTED DICARBOXYLIC ACID LIGANDS AND PRODUCTS THEREOF | STOCKHOLM UNIVERSITY HOLDING AB (SE) | 2017-08-03 | — | — | WO | disclosed |
| WO-2017129991-A2 | PROCESSES FOR PREPARING STERICALLY CONGESTED DICARBOXYLIC ACID LIGANDS AND PRODUCTS THEREOF | STOCKHOLM UNIVERSITY HOLDING AB (SE) | 2017-08-03 | — | — | WO | disclosed |
| US-9340644-B2 | Self-sensitive polymerizable liquid resin and use thereof | ETERNAL MATERIALS CO., LTD. (TW) | 2016-05-17 | — | — | US | disclosed |
| WO-2015110999-A1 | EZH2 INHIBITORS AND USES THEREOF | Piramal Enterprises Limited (IN) | 2015-07-30 | — | — | WO | disclosed |
| US-20130296485-A1 | SELF-SENSITIVE POLYMERIZABLE LIQUID RESIN AND USE THEREOF | ETERNAL CHEMICAL CO., LTD. (TW) | 2013-11-07 | — | — | US | disclosed |
| US-20100298289-A1 | HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS | UCB PHARMA, S.A. (BE) | 2010-11-25 | — | — | US | disclosed |
| US-20100273791-A1 | TRICYCLIC PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CADILA HEALTHCARE LIMITED | 2010-10-28 | — | — | US | disclosed |
| US-20080051386-A1 | Tricyclic Pyrazole Derivatives as Cannabinoid Receptor Modulators | CADILA HEALTHCARE LIMITED (IN) | 2008-02-28 | — | — | US | disclosed |
| US-4124374-A | Alkyl-substituted cycloalkanapyrazole herbicides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1978-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051386-A1 | Tricyclic Pyrazole Derivatives as Cannabinoid Receptor Modulators | CNR2, CNR1, GPR55 | MCL1 2465/4885KMT2A 4196/4885MAPK1 1078/4885 |
| US-20100273791-A1 | TRICYCLIC PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, GPR55 | MCL1 2465/4885KMT2A 4196/4885MAPK1 1078/4885 |
| US-20100298289-A1 | HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS | HRH4, HRH2, HRH3 | MCL1 3445/4885KMT2A 802/4885MAPK1 3898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.